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Introduction
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by the accumulation of fat in hepatocytes. Fifteen percent to 30% of the general population in both the Western world and Asia suffer from NAFLD [1, 2] . The prevalence is increased in type 2 diabetes mellitus (T2DM) (70%) and morbid obesity (90%) [3] . Non-alcoholic steatohepatitis (NASH) is a subset of NAFLD characterized by excessive fat accumulation in hepatocytes (steatosis) associated with liver tissue inflammation. Unlike steatosis alone (simple steatosis, SS), which is generally considered benign and reversible, NASH may progress to fibrosis, cirrhosis and hepatocellular carcinoma [4, 5] . Approximately 2-3% of the global population is supposed to have NASH, tending to rise rapidly along with incidence of obesity, T2DM and the metabolic syndrome [6, 7] . The pathogenesis of NASH appears complex and it is still poorly understood, hence there are no specific therapeutic strategies for NASH.
Fatty acid translocase CD36 (CD36) is a widely expressed membrane glycoprotein, which plays an important role in facilitating the uptake and intracellular trafficking of long-chain fatty acid (LCFA) [8, 9] . Growing evidence indicates that the role played by CD36 extends far beyond the transport of fatty acids (FA). Indeed, CD36 also impacts FA oxidation by influencing the activation of monophosphate-activated protein kinase (AMPK) [10] . More importantly, CD36 is engaged in the regulation of chronic metabolic inflammation. Stewart et al. reported that CD36 ligands (oxidized LDL and amyloid-beta) are able to trigger inflammatory signaling through the assembly of a complex of CD36 and toll-like receptors 4/6 [11, 12] . CD36 deletion markedly reduced adipocyte inflammation in mice fed with a high-fat diet (HFD) by inhibiting the JNK pathway [13] . Accordingly, CD36 has been recognized as a multifunctional immuno-metabolic receptor [14] .
Hepatic CD36 expression is normally weak, but its expression is significantly increased in animal models and patients with steatosis [15, 16] . Hepatic overexpression (OE) of CD36 results in steatosis in mice even in the absence of a high-fat diet (HFD) [17] , and liver-specific knockout (KO) of CD36 reduces liver lipid content when mice were fed with HFD [18] . However, little is known about the role of CD36 in NASH.
It is well-established that CD36 functions are largely dependent on its localization on the plasma membrane [19] . Insulin and the forkhead transcription factor FoxO1 induce CD36 translocation from intracellular depots to the plasma membrane, facilitating FA uptake [20] . However, the mechanisms regulating CD36 localization on the plasma membrane remain poorly understood.
Palmitoylation is the covalent attachment of palmitate to cystein residues of proteins. This post-translational modification increases the lipophilicity of the modified protein, thus regulating its subcellular distribution and function [21] . It has been confirmed that human CD36 is palmitoylated, cysteines residues (cys) 3, 7, 464, and 466 account for the entire palmitoylation of CD36 [22] . Inhibition of palmitoylation causes ER accumulation of CD36 and decreases its incorporation into plasma membrane rafts, thus reducing the efficiency of uptake of oxidized low density lipoprotein in melanoma cell lines [23] .
The functional consequences of palmitoylation of CD36 within the liver and its role in NASH have never been addressed. In the present study, we demonstrated that the localization of CD36 on the plasma membrane of hepatocytes was significantly increased in patients with NASH and we provide detailed mechanistic insights on the role of CD36 palmitoylation in the pathogenesis of NASH in a HFD-induced NASH mice model. The results of the study suggest that CD36 palmitoylation represents a pathogenic link between FA metabolic dysfunction and liver tissue inflammation in NASH.
Materials and Methods
Human samples. The study included 79 non-diabetic liver tissue biopsy samples obtained from the Affiliated Hospital of Chongqing Medical University (CQMU) (9 patients) and Xinhua Hospital of Shanghai Jiaotong University School of Medicine (SJTUSM) (10 patients), China and from the Royal Free Hospital (60 patients), United Kingdom. The liver samples were obtained either by liver biopsy for diagnostic purpose or from surgical liver resections. All patients provided written informed consent for their tissue to be analyzed for research purposes. The study was approved by the Hospital Ethics Committees of CQMU, SJTUSM and the Royal Free Hospital. Main inclusion criteria were daily alcohol consumption <20 g, negative tests for viral infections (hepatitis B virus, hepatitis C virus and human immunodeficiency virus) or other causes of acute or chronic liver diseases.
Tissue sections were reviewed by liver pathologists in Chongqing Medical University and the Royal Free Hospital, and classified/subdivided into four groups: normal liver (NL, n=20), simple steatosis (SS, n=19), NASH (n=21) and cirrhosis (n=19).
Histology, ORO, sirius red staining. Paraffin-embedded tissue sections were routinely stained with hematoxylin and eosin (HE) using standard protocols. Plasmid, lentivirus production and stable cell lines. The mammalian expression plasmid PCI-CD36 encoding wild type human CD36 full-length cDNA was kindly provided by Kenneth J. Linton (Queen Mary, University of London). A CD36 variant was generated using PCI-CD36 as a template and the mutation primers (Supplementary table 1 ) with a multiple site-directed mutagenesis Kit (QuickChange II XL, Agilent Technologies), in which the cysteine pair (Cys-3, 7) of wild type CD36 were replaced with alanine, and the residues towards the carboxyl terminus (Cys-464, 466) were replaced with serine ( Supplementary Figure 2A) .
The lentivirus constructs including GV341 empty vector (NC-vector), GV341 containing wild type CD36 (wt-CD36), AA-SS mutant (AA-SS CD36) were provided by Shanghai GeneChem Company. HepG2 cells were infected with a multiplicity of infection (MOI) of 10 and stable transfectants were selected with puromycin (Shanghai Sangon) and named as NC-HepG2, wt-CD36-HepG2, and AA-SS-HepG2, respectively.
Experimental animals. 8-week-old male C57BL/6J mice were fed with a high fat diet (HFD), (n=6) or normal chow diet (NCD) (n=6) for 22 weeks (research diets 12492, 12109B). In some experiments, the 8-week-old male CD36 knockout (CD36KO) mice were injected with NC lentivirus vectors (n=6), wt-CD36 lentivirus vectors (n=6) and AA-SS lentivirus vectors (n=6) in the tail vein and kept on HFD for 8 weeks. All mice were housed in a temperature-controlled environment and 12 h, 12 h light: dark cycle with free access to diet and water. Paraffin-embedded tissue sections were incubated with anti-CD36 (Novus) and anti-beta catenin (Abcam) followed by an incubation of FITC-labeled anti-rabbit
IgG and TRITC-labeled anti-mouse IgG. Then sections were stained with DAPI and images were captured using a Leica confocal microscope. The Pearson's correlation (R value) and co-localization rate were analyzed from four different fields in each sample using Leica confocal microscope software. The band intensity was analyzed by densitometry software (Image J).
Quantitative analysis of hepatic triglyceride (TG
Detection of CD36 protein palmitoylation. Protein palmitoylation was assessed by immunoprecipitation and acyl-biotin exchange (IP-ABE) as previously described [24] . Briefly, total protein was extracted using a lysis buffer with protease inhibitors and N-ethylmaleimide (NEM). After precipitating CD36 protein with anti-CD36body (Novus) and magnetic beads (Millipore), samples were re-suspended with stringent buffer. Added 0.5 ml/sample of lysis buffer pH 7.2 to all -hydroxylamine (HAM) samples, and 0.5 ml/ sample of HAM buffer to all +HAM samples. All samples were rotated at room temperature for 50min. Then samples were added with Biotin-BMCC buffer, and rotated for 50min at 4 . Proteins were eluted from the beads by boiling in sample buffer and the cleared supernatants were resolved by SDS-PAGE and electro-transferred to PVDF membranes (Millipore). For detecting palmitoylated CD36, membranes were incubated with HRP-conjugated anti-streptavidin for 1 hour at 37°C. For detecting total CD36, membranes were incubated with anti-CD36 (Novus) and subsequent HRP-conjugated secondary antibody (Zsbio).
NF-κB activity assay. Cells were transfected with an NF-κB response element-luciferase reporter gene and reporter gene activity was measured using the Dual Luciferase Assay Reporter System (Promega) as previously described [11] . 
Isolation and analysis of detergent-resistant membranes (DRMs).
Plasma membrane lipid rafts were identified as DRMs and were obtained by floatation on sucrose density gradients by ultracentrifugation of Triton X-100
lysates as previously described [25] . The partitioning of CD36 to the DRM and non-DRMs fractions was determined using Image J software. The data were exported and analyzed using a previously reported bivariate spreadsheet method [26] with some modification. Briefly, all cell event data were categorized according to the levels of expression of CD36 in SPSS software. After excluding channels below three cell events, the mean and standard deviates of fluorescence values for ligand (FL-C16) were calculated for each receptor (CD36) level category. Then these data were exported into EXCEL2007 and a Student's t-test was performed to compares the binding/uptake of ligand for receptor categories displaying equivalent receptor expression between two groups. The average of FL-C16 uptake vs. CD36 expression and statistical results were plotted using EXCEL. 
Measurements of O

Results
CD36 localization on the hepatocellular plasma membrane is
significantly increased in patients with NASH. Compared with the NL group, evident lipid droplets were observed in livers of the patients with SS (Figure 1Aii ), while steatosis was associated with evident inflammatory cell infiltration in liver sections from patients with NASH ( Figure 1A iii). A hepatic steatosis index was evaluated by measuring the percentage of the liver tissue area occupied by fatty hepatocytes, as described in Methods. As shown in Figure 1B , the hepatic steatosis index was similar in patients with SS and NASH and was significantly higher than in NL and cirrhotic patients. On the other hand, both Sirius red staining and the hepatic fibrosis index were significantly higher in patients with NASH and cirrhosis ( Figure 1C and 1D ).
As β-catenin is localized on the hepatocyte plasma membrane, we next investigated CD36 distribution on the plasma membrane of hepatocytes in samples of normal liver (NL) as well as from patients with different stages of NAFLD (SS, NASH and cirrhosis), using a dual-staining of CD36 and β-catenin.
The CD36 expression was weak in the liver samples from NL subjects ( Figure 1E v), but it was increased in the patients with SS ( Figure 1E vi) and NASH ( Figure 1E vii), and became weak again in cirrhotic patients ( Figure 1E viii). More importantly, the localization of CD36 on hepatocytes plasma membrane was significantly increased in NASH patients ( Figure 1E xi and xv). We further quantified the colocalization efficiency of CD36 and β-catenin in this group of patients. As shown in Figure 1F , the Pearson's correlation (R value of CD36 and β-catenin staining) was higher in patients with SS than in those with NL and was highest in NASH patients, suggesting that the localization of CD36 on the plasma membrane of hepatocytes is positively correlated with the evolution from NL to SS and to NASH.
Notably, the R value was lower in cirrhosis than with NASH, which may be due to massive loss of hepatocytes in cirrhotic livers ( Figure 1F ). The co-localization rate was also significantly increased in the patients with NASH compared with subjects with NL or SS or cirrhosis ( Figure 1G ). These findings further support that CD36 localization on the plasma membrane of hepatocytes is associated with the development of NASH.
CD36 palmitoylation is induced in the liver of mice with NASH. Since palmitoylation is closely related to the translocation of membrane protein from an intracellular pool to the plasma membrane, we investigated the role of hepatic Figure 2B) . Palmitoylated CD36 levels were significantly higher in wt-CD36-HepG2 cells than in NC-HepG2 cells. In contrast, the levels of palmitoylated CD36 to total CD36 in AA-SS-HepG2 cells were almost equal to NC-HepG2 cells (Supplementary Figure 2C) .
Next, we injected CD36KO mice with lentivirus vectors to express wt-CD36
and AA-SS CD36. As endogenous CD36 was absent in this model, its effects were excluded. As shown in Figure 3A , CD36 protein was absent in the livers of CD36KO mice, while it was significantly increased in hepatocytes of CD36KO-wt The TG quantitative data also showed that hepatic content of TG in CD36KO-wt CD36 mice was significantly higher than in CD36KO-NC and CD36KO-AA SS mice ( Figure 3E ). The hepatic mRNA levels of cytokines/chemokine (TNFα, IL-6
and MCP-1) and fibrosis markers (collagen IV and TGFβ) were significantly increased in CD36KO-wt CD36 mice, whereas the expression of these genes was significantly reduced in the CD36KO-AA SS mice ( Figure 3F and 3G ). These findings clearly demonstrated that CD36 palmitoylation represents a mechanistic step in the development of NASH. Figure   4D ). Furthermore, as shown in Figure 4E , a weaker CD36 plasma membrane signal contrasted with a stronger CD36 cytoplasm signal in AA-SS-HepG2, as compared to wt-CD36-HepG2 cells.
Given that the plasma lipid raft is an essential domain for CD36-mediated FA uptake [28] , we further investigated the impact of inhibition of CD36 palmitoylation on its distribution in the lipid rafts of HepG2 cells. DRM analysis revealed that CD36 from the wt-CD36-HepG2 was highly enriched within the visible floating band that also contained caveolin, a lipid raft marker, while CD36 in the AA-SS-HepG2 cells was less evident within the DRM fractions ( Figure 4F ). This pattern of distribution was confirmed to be statistically significant and consistent in different preparations ( Figure 4F ). AMPK is a key regulator in the maintenance of cellular FA homeostasis [29] , which controls FA β-oxidation in mitochondria. As shown in Figure 6D 
Inhibition of CD36 palmitoylation reduces long
Discussion
Lipid accumulation and tissue inflammation are key features of NASH.
However, the pathogenic cross-roads linking FA metabolism, lipotoxicity and hepatic inflammation/fibrogenesis remain unclear. CD36 is a widely expressed membrane glycoprotein playing an important role in modulating FA uptake and FA β-oxidation, contributing to the maintenance of cellular FA homeostasis [10, 31] . In addition, CD36 regulates a downstream pathway modulating NF-κB activity which activates cellular inflammatory response [11, 12] . In these terms, CD36 represents a crucial link between FA metabolic dysregulation and inflammation, which synergistically contributes to the development of NASH.
Previously, the potential role of CD36 in the pathogenesis of human NAFLD was suggested by the study of Miquilena-Colina et al., showing that CD36
is overexpressed and associated with insulin resistance, hyperinsulinemia and increased steatosis in patients with NAFLD and HCV with fatty liver [32] . In the present study, we confirmed that CD36 expression increased with evolution from normal liver to SS and further development to NASH. Since CD36 is widely expressed in many cell types, including monocytes, macrophages and hepatocytes [33] , we characterized CD36 distribution on the hepatocellular plasma membrane using co-immunofluorescent staining of CD36 and β-catenin, a hepatocyte plasma membranes marker. Our results show that the distribution of [34, 35] . In addition, Thorne et al. consistently found that palmitoylation is necessary for the efficient incorporation of CD36 into plasma membrane rafts in melanoma cells [23] . Therefore, the role of CD36 palmitoylation in the development of NASH was investigated in the present study. We examined Consequently, the palmitoylated CD36 on the hepatic plasma membrane mediates FA uptake and enhances the formation of the CD36/Lyn/Fyn complex with the consequent activation of an inflammatory cascade, which distinguishes NASH from SS. Accordingly, inhibition of CD36 palmitoylation leads to the inactivation of the NF-κB signaling pathway, followed by reduced inflammatory reaction both in vivo and in vitro. JNK plays an important role in the development of NASH. Deletion of JNK diminishes hepatic inflammation induced by a high-fat diet and a methionine-and choline-deficient (MCD) diet respectively in mice, [37, 38] .
The activation of JNK in response to multiple stresses mediates inflammation through activator protein-1-dependent transcription of proinflammatory cytokines [30] . CD36 recruits the src kinase Lyn, which phosphorylates and activates JNK, contributing to adipose tissues inflammation [39] . The interaction between CD36
and src kinase Lyn required the MISY motif on 460-463 amino acids residues of C-terminus of CD36 [11] , which is near by the palmitoylation sites on the C-terminus of CD36 (residues 464 and 466). In this study, we show that the absence of CD36 palmitoylation significantly decrease the interaction between CD36 and Lyn, resulting in reduced JNK activation and inflammatory responses.
Since inflammatory stress affects multiple steps in FA metabolisms, resulting in hepatic steatosis [40] , the attenuated inflammation may also contribute to the reduced lipid accumulation in the liver.
Interestingly, inhibition of CD36 palmitoylation, either by mutations of palmitoylation sites (AA-SS) of CD36 or pharmacological agent, inhibited FA binding, uptake and an inflammatory response. In the present study, the specific role of CD36 palmitoylation was identified by the mutation on CD36 palmitoylation sites. Wild type CD36 (wt-CD36) overexpression caused steatosis and inflammation in mice livers, while mice bearing the palmitoylation-sites mutated CD36 (AA-SS) did not develop NASH. 2-BP, which is not a specific inhibitor of CD36 palmitoylation although they have been widely used to test the general role of palmitoylation of protein [23] , prevented the development of hepatic steatosis.
Accordingly, more specific inhibitors of CD36 palmitoylation should be considered in future studies for the treatment/prevention of NASH.
The excess of lipids in hepatic steatosis is mainly constituted by TG, which are stored in cytoplasmic lipid droplets [41] . Excessive influx of FA from the circulation to the liver is normally handled by FA β-oxidation. However, lipid overload particularly in the presence of tissue inflammation leads to the impairment of FA β-oxidation, as shown in this study, and leads to the worsening of steatosis. AMPK plays an important role in maintaining energy homeostasis and may have therapeutic importance for treating obesity, insulin resistance, type 2 diabetes, cardiovascular disease and hepatic steatosis [42] . AMPK is normally quiescent, and it is phosphorylated and activated in response to energy stresses, leading to a decrease in ATP-consuming pathways and an increase in ATP-producing pathways. Liver-specific activation of AMPK completely protects mice against high-fructose diet-induced hepatic steatosis [43] . Hepatic activation of AMPK has been reported to promote FAO via phosphorylation and inactivation of ACC, reducing levels of the β-oxidation inhibitor malonyl-CoA [44] . Previous studies have demonstrated that CD36 is presented in a protein complex with the AMPK kinase LKB1 (liver kinase B1) and the src kinase Fyn [10] . Wt-CD36 overexpression promotes Fyn mediated LKB1 phosphorylation and its nuclear sequestration, hindering LKB1 mediated phosphorylation and activation of AMPK [45] . Consistent with this, we found that palmitoylation of CD36 is associated with a low AMPK activity, accompanying a low hepatic FA β-oxidation, which may also due to the increased LKB1 phosphorylation, a negative regulator of AMPK. On the In conclusion, the present study provides sound evidence for suggesting that distribution of CD36 on cellular plasma membrane, rather than simply its level of expression, plays a key role in the pathogenesis of NASH. As palmitoylation controls the distribution and functions of CD36, targeting the palmitoylation sites of CD36 may offer a new therapeutic strategy for the treatment of NASH and its progression to advanced chronic liver disease. Data were presented as mean ± SEM. The difference between two groups was statistically analyzed by Student's t-test. * P<0.05 vs.wt-CD36 groups. 43  62  81  100  119  138  157  176  195  214  233  252  271  290  309  328  347  366  385  404  423  442  461 Kyte-Doolittle 
